Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients.

Matteo BargagliAndri VetschManuel A AndereggNasser A DhayatUyen Huynh-DoNicolas FallerBruno Vogt Pietro Manuel Ferraro Daniel G Fuster

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)

Chronic Tolvaptan treatment is associated with increased femoral bone mineral density and significant changes in both mineral metabolism and acid-base parameters in ADPKD patients.

Keyphrases

bone mineral density
postmenopausal women
end stage renal disease
body composition
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
heart failure
patient reported outcomes
replacement therapy